Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rahul Mudumba

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 13, 2025
First-Line Alectinib, Brigatinib, and Lorlatinib for Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Cost-Effectiveness AnalysisRahul Mudumba, Jorge J Nieva, William V Padula
Journal of Managed Care & Specialty Pharmacy|August 30, 2025
Real-world costs, treatment patterns, and clinical outcomes associated with treatments for advanced anaplastic lymphoma kinase-positive non-small cell lung cancerRahul Mudumba, Xiaofan Liu, Ian Davis, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 2, 2023
Cost-Effectiveness Analysis of Trastuzumab Deruxtecan Versus Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 Positive Metastatic Breast Cancer in the United StatesRahul Mudumba, Hui-Hsuan Chan, Yuan-Yuan Cheng, et al.
Lung Cancer (Amsterdam, Netherlands)|May 14, 2026
Comparative effectiveness of first-line targeted therapies in ALK-positive non-small cell lung cancer: real-world evidence of tyrosine kinase inhibitorsRahul Mudumba, Xiaofan Liu, Shihan Jin, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 13, 2025
First-Line Alectinib, Brigatinib, and Lorlatinib for Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Cost-Effectiveness AnalysisRahul Mudumba, Jorge J Nieva, William V Padula
Journal of Managed Care & Specialty Pharmacy|August 30, 2025
Real-world costs, treatment patterns, and clinical outcomes associated with treatments for advanced anaplastic lymphoma kinase-positive non-small cell lung cancerRahul Mudumba, Xiaofan Liu, Ian Davis, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 2, 2023
Cost-Effectiveness Analysis of Trastuzumab Deruxtecan Versus Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 Positive Metastatic Breast Cancer in the United StatesRahul Mudumba, Hui-Hsuan Chan, Yuan-Yuan Cheng, et al.
Lung Cancer (Amsterdam, Netherlands)|May 14, 2026
Comparative effectiveness of first-line targeted therapies in ALK-positive non-small cell lung cancer: real-world evidence of tyrosine kinase inhibitorsRahul Mudumba, Xiaofan Liu, Shihan Jin, et al.
Pageof 1